Navigation Links
Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/-- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and CEO James A. Joyce will be the lead-off presenter at the Biotech Showcase™ 2012. Mr. Joyce's presentation will begin at 9:00 am Pacific Time on January 9th, 2012.  A live webcast of the presentation will be available at:

http://www.media-server.com/m/p/dfvbu2du

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

About Biotech Showcase™

Biotech Showcase™ is a forum devoted to providing biotechnology companies, investors and pharmaceutical executives with an opportunity to meet in one place during the course of one of the world's largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-to-one partnering meetings and networking. The attendees to the showcase include private and public equity investors, analysts, bankers, biopharmaceutical industry executives and other industry professionals.  The event is being held at the Parc 55 Wyndham San Francisco – Union Square. 

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com

 

 

 

 


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
2. Aethlon Medical Releases Shareholder Letter
3. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
4. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
5. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
6. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
7. Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
8. Aethlon Medical Releases Shareholder Letter
9. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
10. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
11. Aethlon Medical Clarifies News Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced ... ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of ... Tribute. The combined company will operate under Aralez Pharmaceuticals ... in Canada , Ireland ... . Under the terms of the Agreement and Plan ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier Medical ... or the "Company"), which develops, markets and sells ... China and international markets, ... which aims to concentrate the Company,s resources to ... respiratory business and to focus more on its ...
(Date:2/5/2016)... February 4, 2016 France , ... , UK, and Israel ). It includes a ... and 3 GD, segmented by age and sex in these markets. GD ... EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis ... , Germany , Italy , ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... San Francisco, CA (PRWEB) , ... February 05, ... ... dentist and founder of CitiDent, announces that it is now welcoming ... by Dr. Cheng, CitiDent offers a complete range of oral health care, including ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
(Date:2/5/2016)... ... ... California Mobile Kitchens , a company that designs ... kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. , ... in the U.S. Many of their units can be seen at sporting events, ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. ... fixed known bugs within the app. Calls Blacklist allows its users to only have ... of their device’s battery power or memory. It provides a powerful call blocker that ...
Breaking Medicine News(10 mins):